| Also known as |
Champix in some countries, Chantix in the USA |
| Blood pressure |
Generally has no significant effect on blood pressure |
| Chemical name |
(7aS)-7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine |
| Dosage (medical) |
Typically starts with 0.5 mg once daily for the first 3 days, then 0.5 mg twice daily for the next 4 days, then 1 mg twice daily thereafter |
| Dosage (sports) |
Not applicable |
| Effects |
Reduces craving and withdrawal symptoms associated with quitting smoking |
| Formula |
C13H13N3 |
| Half-life |
Approximately 24 hours |
| Hepatotoxicity |
Minimal to none |
| Lab Test |
Not typically monitored with lab tests |
| Main action |
Smoking cessation aid |
| Raw Material |
Varenicline |
| Side effects |
Nausea, headache, vomiting, flatulence, insomnia, abnormal dreams, and changes in taste |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Substance class |
Partial nicotinic acetylcholine receptor agonist |
| Trade name |
Chantix, Champix |
| Use in sports |
Not typically used in sports |
| Water Retention |
No significant water retention |
| Manufacturer |
Pfizer |
| Packing |
11 tabs / 0,5 mg ,42 tabs / 1 mg |
